Based on 28 histologically well-established cases of chronic non-suppurative destructive cholangitis, clinico-pathological aspects of differential diagnosis and staging are reported. In only half of the cases could the diagnosis be made on the first liver biopsy. In 14 cases, two or more liver biopsy specimens were necessary for diagnosis. The most frequent and most difficult differential diagnostic issue was to distinguish between chronic non-suppurative destructive cholangitis and chronic aggressive hepatitis of viral or autoimmune origin. The histochemical demonstration of copper by the rhodanine method was of particular value for differentiating between chronic non-suppurative destructive cholangitis and chronic aggressive hepatitis as well as for diagnosis of mixed types. In two cases of mixed type, the HBs-Antigen in ground glass hepatocytes and copper-associated protein in periportal hepatocytes could be demonstrated simultaneously with Shikata's Orcein-staining. Compared with the previously used system (Scheuer 1967) the staging concept proposed by Ludwig et al. (1978) has proved to be more useful and easier to apply. This system permits recognition of the stage on routinely obtained specimens regardless of specific differential diagnostic features. Most liver biopsy specimens were assigned to stage III. Features considered characteristic of the earlier phases (inflammatory bile duct destruction and granulomas) frequently coexist with more advanced lesions in late stage.

Download full-text PDF

Source

Publication Analysis

Top Keywords

destructive cholangitis
16
chronic non-suppurative
12
non-suppurative destructive
12
liver biopsy
12
diagnosis staging
8
biopsy specimens
8
differential diagnostic
8
cholangitis chronic
8
chronic aggressive
8
aggressive hepatitis
8

Similar Publications

Introduction: Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease causing bile duct destruction and inflammation, impacting patient quality of life (QoL) due to variable symptoms. Digital symptom-tracker apps may improve patient care through enhanced monitoring. This feasibility study reassessed symptom burden in PBC patients using a tailored symptom-tracker app, focusing on its usability, effectiveness, and impact on management and QoL.

View Article and Find Full Text PDF

The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.

Hepatology

January 2025

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.

Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease characterized by the progressive destruction of intrahepatic bile ducts, leading to fibrosis, and potentially cirrhosis. PBC has been considered a prototypical autoimmune condition, given the presence of specific autoantibodies and the immune response against well-defined mitochondrial autoantigens. Further evidence supports the interaction of immunogenetic and environmental factors in the aetiology of PBC.

View Article and Find Full Text PDF

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.

Hepatol Commun

January 2025

Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.

Article Synopsis
  • Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are liver diseases that damage bile ducts, leading to bile accumulation, liver injury, and increased risk of liver failure; current treatments are limited, especially for PSC.
  • Ursodeoxycholic acid is the first-line treatment for PBC, but many patients do not respond fully, indicating a need for better therapies; pruritus (itching) is a common and severe symptom due to cholestasis that is often inadequately treated.
  • The review examines the use of PPAR agonists, a type of medication that targets liver metabolism, as potential second-line treatments for PBC and PSC, highlighting recent FDA approvals for
View Article and Find Full Text PDF

Racial Disparities in Inpatient Hospital Outcomes of Primary Sclerosing Cholangitis in United States: Nationwide Analysis.

Diagnostics (Basel)

November 2024

Parkview Cancer Institute, Advanced Interventional Endoscopy & Endoscopic Oncology (IOSE) Division, GI Oncology Program, 11104 Parkview Circle, Suite 310, Fort Wayne, IN 46845, USA.

Article Synopsis
  • Primary sclerosing cholangitis (PSC) is a liver disease linked to inflammatory bowel disease and can cause serious liver complications; this study investigates trends in healthcare usage and mortality related to PSC in the U.S. from 2008 to 2017.
  • The analysis of the Nationwide Inpatient Sample reveals that while hospital charges for PSC patients rose by 32.2%, the average length of hospital stays decreased during the study period, indicating changes in healthcare practices.
  • Additionally, there was a notable increase in the severity of illness and risk of death among PSC patients, with a rise in cases of hepatocellular carcinoma (HCC), while cases of cholangiocarcinoma (CCA) saw a decline.
View Article and Find Full Text PDF

Background: Langerhans cell histiocytosis (LCH) is a systemic neoplasia with diverse clinical manifestations, predominantly affecting bone and skin. However, in children, LCH presenting primarily with cholestasis is rare.

Case Summary: We present the case of a 22-month-old boy who was admitted to our hospital with a history of intermittent fever and abdominal distension for over 2 months, and jaundice for over 1 month.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!